Lineage Cell Therapeutics (LCTX) Net Income towards Common Stockholders (2010 - 2026)
Lineage Cell Therapeutics' (LCTX) quarterly Net Income towards Common Stockholders came in at -$4.8 million in Q1 2026, up 29.34% year-on-year from -$3.7 million in Q1 2025, and up 17.33% quarter-over-quarter from -$5.8 million in Q4 2025.
Lineage Cell Therapeutics (LCTX) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at -$4.8 million for Q1 2026.
- On a quarterly basis, Net Income towards Common Stockholders rose 29.34% year-over-year to -$4.8 million in Q1 2026; TTM through Mar 2026 was -$52.0 million, a 176.18% decrease from a year earlier, with the FY2025 full-year figure at -$63.4 million, down 241.01% from the prior year.
- Net Income towards Common Stockholders grew to -$4.8 million in Q1 2026 per LCTX's latest filing, from -$5.8 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$3.0 million in Q3 2024 and bottomed at -$22.5 million in Q2 2025.
- The 5-year median for Net Income towards Common Stockholders is -$6.1 million (2022), against an average of -$7.4 million.
- Across the five-year window, Net Income towards Common Stockholders jumped 77.43% in 2022 and sank 528.02% in 2025, its largest moves.
- Year by year, Net Income towards Common Stockholders stood at -$6.3 million in 2022, then rose by 25.42% to -$4.7 million in 2023, then surged by 31.06% to -$3.2 million in 2024, then slumped by 79.11% to -$5.8 million in 2025, then advanced by 17.33% to -$4.8 million in 2026.
- Per Business Quant, the three latest LCTX Net Income towards Common Stockholders figures stand at -$4.8 million (Q1 2026), -$5.8 million (Q4 2025), and -$18.8 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,921.77 Bn | 66,921.49 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,924.26 Bn | 1,924.20 Bn | - | - |
| 3 | Akari Therapeutics | 975.59 Bn | 975.59 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.47 Bn | 466.67 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.76 Bn | 114.52 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.90 Bn | 61.15 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.83 Bn | 62.83 Bn | - | -0.68 |
| 8 | Argenx Se | 55.77 Bn | 50.59 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Revolution Medicines | 37.45 Bn | 37.45 Bn | - | -453.82 Mn |
| 10 | Lineage Cell Therapeutics | 252.38 Mn | 189.66 Mn | 1.73 Mn | -4.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.81 Mn |
| Dec 31, 2025 | -5.82 Mn |
| Sep 30, 2025 | -18.85 Mn |
| Jun 30, 2025 | -22.54 Mn |
| Mar 31, 2025 | -6.81 Mn |
| Dec 31, 2024 | -3.25 Mn |
| Sep 30, 2024 | -3.00 Mn |
| Jun 30, 2024 | -5.77 Mn |
| Mar 31, 2024 | -6.56 Mn |
| Dec 31, 2023 | -4.71 Mn |
| Sep 30, 2023 | -7.16 Mn |
| Jun 30, 2023 | -5.20 Mn |
| Mar 31, 2023 | -4.40 Mn |
| Dec 31, 2022 | -6.32 Mn |
| Sep 30, 2022 | -6.08 Mn |
| Jun 30, 2022 | -6.78 Mn |
| Mar 31, 2022 | -7.09 Mn |
| Dec 31, 2021 | -28.01 Mn |
| Sep 30, 2021 | -7.83 Mn |
| Jun 30, 2021 | -4.97 Mn |